Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats

Stroke

Volumn 34, Issue 3, 2003, Pages 758-763

  Belayev, Ludmila ^a   Khoutorova, Larissa ^a   Deisher, Theresa A ^b   Belayev, Andrey ^a   Busto, Raul ^a   Zhang, Yongbo ^a   Zhao, Weizhao ^a   Ginsberg, Myron D ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

Author keywords

Brain edema; Cerebral ischemia; Focal; Middle cerebral artery occlusion; Neuroprotection; Rats

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD39 ANTIGEN; SOLUBLE CD39 ANTIGEN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD VESSEL; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN PERFUSION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIGENS, CD; APYRASE; BEHAVIOR, ANIMAL; BRAIN; BRAIN EDEMA; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; SERUM ALBUMIN; TIME FACTORS;

EID: 0037338554     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000056169.45365.15     Document Type: Article

References (29)

1. Fieschi C, Argentino C, Lenzi GL, Sacchetti ML, Toni D, Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci. 1989;91:311-321.
2. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
3. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest. 2001;119:300S-320S.
4. Abumiya T, Fitridge R, Mazur C, Copeland BR, Koziol JA, Tschopp JF, Pierschbacher MD, del Zoppo GJ. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke. 2000;31:1402-1409.
5. Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, Kottirsch G, Pinsky DJ. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest. 1998;102:1301-1310.
6. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 1993;7:516-522.
7. Marcus AJ, Broekman MJ, Drosopoulos JH, Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN, Schoenborn MA, Schooley KA, Gayle RB, Maliszewski CR. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest. 1997;99:1351-1360.
8. Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Jr, Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. 2002;109:1031-1040.
9. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
10. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke. 1996;27:1616-1622.
11. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg. 1997;87:595-601.
12. Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, Busto R, Ginsberg MD. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29:2587-2599.
13. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32:553-560.
14. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
15. De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PJ. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 1989;20:1383-1390.
16. Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke. 1992;23:1167-1173.
17. Kissel P, Chehrazi B, Seibert JA, Wagner FC Jr. Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator. J Neurosurg. 1987;67:399-405.
18. Gayle RB III, Maliszewski CR, Gimpel SD, Schoenborn MA, Caspary RG, Richards C, Brasel K, Price V, Drosopoulos JH, Islam N, Alyonycheva TN, Broekman MJ, Marcus AJ. Inhibiton of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest. 1998;101:1851-1859.
19. Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, Hancock WW, Bach FH. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 1997;185:153-163.
20. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem. 1996;271:33116-33122.
21. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
22. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
23. Camarata PJ, Heros RC, Latchaw RE. "Brain attack": the rationale for treating stroke as a medical emergency. Neurosurgery. 1994;34:144-157.
24. Grabowski M, Brundin P, Johansson BB. Paw-reaching, sensorimotor, and rotational behavior after brain infarction in rats. Stroke. 1993;24:889-895.
25. Garcia JM, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats: statistical validation. Stroke. 1995;26:627-634.
26. DeVries AC, Nelson RJ, Traystman RJ, Hum PD. Cognitive and behavioral assessment in experimental stroke research: will it prove useful? Neurosci Biobehav Rev. 2001;25:325-342.
27. Yamamoto M, Tamura A, Kirino T, Shimizu-Sasamata M, Sano K. Effects of thyrotropin-releasing hormone on behavioral disturbances in middle cerebral artery-occluded rats. Eur J Pharmacol. 1991;197:117-123.
28. Wahl F, Allix M, Plotkine M, Boulu RG. Neurological and behavioral outcomes of focal cerebral ischemia in rats. Stroke. 1992;23:267-272.
29. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000;39:777-787.